This week we take a (brief) stop back in time to the beginning of dostarlimab's journey that has ended (for now) in an accelerated approval for rectal cancer that is mismatch repair-deficient or high in micro-satellite instability (MMRd/h-MSI).
Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Mais episódios de "OncoPharm"



Não percas um episódio de “OncoPharm” e subscrevê-lo na aplicação GetPodcast.








